Background Cardiovascular disease (CVD) risk prediction is important for guiding the
intensity of therapy in CVD prevention. Whilst current risk prediction algorithms use …

Janus kinase (JAK) inhibitors, including tofacitinib, baricitinib, upadacitinib and filgotinib, are
increasingly used in the treatment of rheumatoid arthritis (RA). There has been debate about …

Background Testosterone is the standard treatment for male hypogonadism, but there is
uncertainty about its cardiovascular safety due to inconsistent findings. We aimed to provide …

Background Randomised clinical trials showed that compared with placebo, SGLT2
inhibitors and GLP-1 receptor agonists reduced risk of adverse cardiovascular events. The …

Since their first appearance in the context of schizophrenia and bipolar disorder in 2009,
polygenic risk scores (PRSs) have been described for a large number of common complex …

Background & Aims Chronic liver disease (CLD) is associated with increased cardiovascular
disease (CVD) risk. We investigated whether early signs of liver disease (measured by iron …

Aims: As the impact of inclisiran in stroke prevention in atherosclerotic cardiovascular
disease (ASCVD) patients or those at high risk of ASCVD is still unclear, we conducted a …

Importance Cardiotoxicity is a serious adverse effect that can occur in women undergoing
treatment for breast cancer. Identifying patients who will develop cardiotoxicity remains …

Background: Whether trends in insulin resistance changes are related to the risk of
cardiovascular disease (CVD) incidence and mortality remains unclear. We aimed to …

Abstract Background Major Adverse Cardiovascular Events (MACE) are common
complications of type 2 diabetes mellitus (T2DM) that include myocardial infarction (MI) …